The 2026 China Innovation Drug New Year Outlook Conference and the inaugural Innovation Drug "Huashan Award" ceremony were successfully held in Shanghai. The "Huashan Award" was jointly launched by "Yixuejie" and "Tongxieyi", selecting industry benchmarks with a professional stance and international standards. Upholding the principles of scientific professionalism and innovation encouragement, it aims to discover China's most influential innovation drug value benchmarks, facilitating industrial upgrading and global development. Biokin Pharmaceutical, with its outstanding performance in international cooperation and technological breakthroughs of core products, was awarded the "Best Potential Innovative Pharmaceutical Enterprise Award".

The "Best Potential Innovative Pharmaceutical Enterprise Award" focuses on the company's "technology and platform innovation" and "R&D pipeline breakthrough potential", particularly emphasizing whether the enterprise possesses self-owned intellectual property technology platforms and whether its leading projects have clear potential to become First-in-Class (FIC) or Best-in-Class (BIC).

The "Huashan Award" evaluates Chinese innovative drug enterprises alongside multinational pharmaceutical companies, and Chinese original innovative drugs alongside those from multinational corporations, aiming to select the most valuable innovative drugs and enterprises in the Chinese market. It strives to continuously promote the industry's global development and help Chinese innovative pharmaceutical companies and their achievements further advance onto the world stage.